Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

Apr 04, 2019

|

NEW YORK (GenomeWeb) – Myriad Genetics announced today it has expanded its collaboration with AstraZeneca and Merck to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer (mCRPC) and germline BRCA mutations who are likely to respond to olaparip (Lynparza).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

To read the full story....

Breaking News

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Featured White Papers

What's Popular?

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Full BRCA1 Gene Deletion Suspected to Contribute to Patient's Long PARP Inhibitor Response

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Sponsorships